This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of VLTS-589 in Subjects With Intermittent Claudication

This study has been completed.
Information provided by:
Valentis Identifier:
First received: September 8, 2003
Last updated: June 23, 2005
Last verified: May 2005
The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.

Condition Intervention Phase
Intermittent Claudication Peripheral Vascular Disease Genetic: Plasmid based Gene Transfer product-VLTS-589 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease

Resource links provided by NLM:

Further study details as provided by Valentis:

Estimated Enrollment: 100
Study Start Date: June 2003
Estimated Study Completion Date: June 2005

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Men or women between 40 and 80 years of age,
  • Must give informed consent,
  • Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness

Exclusion criteria:

  • Ulcers or gangrene,
  • History of cancer (except skin cancer) within the past 5 years,
  • Participation in another clinical trial within 30 days of enrollment in this trial,
  • Unwillingness or inability to comply with all study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00068133

  Show 20 Study Locations
Sponsors and Collaborators
  More Information Identifier: NCT00068133     History of Changes
Other Study ID Numbers: VLTS-589-121
Study First Received: September 8, 2003
Last Updated: June 23, 2005

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Arterial Disease
Intermittent Claudication
Peripheral Vascular Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Signs and Symptoms processed this record on June 23, 2017